Xention: Xention Limited Commences First Phase 2 Study Of XEN-D0103 In Atrial Fibrillation

CAMBRIDGE, UK XENTION LTD ("Xention"), the Cambridge-based biopharmaceutical company specialising in the discovery and development of ion channel-modulating anti-arrhythmic drugs, announced today that the phase 2 development of its lead atrial fibrillation programme ("AF") is underway.In 2013, Xention entered into an agreement with Servier for the development and commercialisation...